EUVIMEDEUVIMED entdecken
Open Access

B-1 B Cell–Derived Natural Antibodies against N -Acetyl- d -Glucosamine Suppress Autoimmune Diabetes Pathogenesis

J Stewart New, Brian L P Dizon, R Glenn King iD, Neil S Greenspan, John F Kearney iD

The Journal of Immunology · 2023

DOI: 10.4049/jimmunol.2300264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2023. Verfasst von J Stewart New und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIAMS NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Environmental factors and host microbiota strongly influence type 1 diabetes (T1D) progression. We report that neonatal immunization with group A Streptococcus suppresses T1D development in NOD mice by promoting clonal expansion of N-acetyl-d-glucosamine (GlcNAc)-specific B-1 B cells that recognize pancreatic β cell–derived Ags bearing GlcNAc-containing posttranslational modifications. Early exposure to Lancefield group A cell-wall carbohydrate Ags increased production of GlcNAc-reactive serum Abs and enhanced localization of innate-like GlcNAc-specific B cells to pancreatic tissue during T1D pathogenesis. We show that B-1 B cell–derived GlcNAc-specific IgM engages apoptosis-associated β cell Ags, thereby suppressing diabetogenic T cell activation. Likewise, adoptively transferring GlcNAc-reactive B-1 B cells significantly delayed T1D development in naive recipients. Collectively, these data underscore potentially protective involvement of innate-like B cells and natural Abs in T1D progression. These findings suggest that previously reported associations of reduced T1D risk after GAS infection are B cell dependent and demonstrate the potential for targeting the natural Ab repertoire in considering therapeutic strategies for T1D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1MiceAnimalsMice, Inbred NODGlucosamineAcetylglucosaminePancreas

Substanzen

GlucosamineAcetylglucosamine

Autor:innen und Institutionen

  • Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL.
  • Department of Pathology, Case Western Reserve University, Cleveland, OH.

ORCID-Profile: R Glenn King, John F Kearney

Förderung

  • NIAID NIH HHS
  • NIAMS NIH HHS
  • NIDDK NIH HHS
  • NCRR NIH HHS
  • HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
  • HHS | NIH | NIAID | Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Zitieren

APA

New, J. S., Dizon, B. L. P., King, R. G., Greenspan, N. S., & Kearney, J. F. (2023). B-1 B Cell–Derived Natural Antibodies against N -Acetyl- d -Glucosamine Suppress Autoimmune Diabetes Pathogenesis. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2300264

Vancouver

New JS, Dizon BLP, King RG, Greenspan NS, Kearney JF. B-1 B Cell–Derived Natural Antibodies against N -Acetyl- d -Glucosamine Suppress Autoimmune Diabetes Pathogenesis. The Journal of Immunology. 2023. doi:10.4049/jimmunol.2300264

BibTeX
@article{New2023,
  author = {New, J Stewart and Dizon, Brian L P and King, R Glenn and Greenspan, Neil S and Kearney, John F},
  title = {B-1 B Cell–Derived Natural Antibodies against N -Acetyl- d -Glucosamine Suppress Autoimmune Diabetes Pathogenesis},
  journal = {The Journal of Immunology},
  year = {2023},
  doi = {10.4049/jimmunol.2300264}
}
Kostenlos starten →